Watch Demo

Cancer Diagnostics Market Research Report by Diagnostic Type, Indication, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

Cancer Diagnostics Market Research Report by Diagnostic Type, Indication, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
  • Publish Date:January 2023

  • Number of Pages:229

  • Report ID:6389179

  • Format:PDF

  • Publisher:360iResearch

$ 3949

Summary

Cancer Diagnostics Market Research Report by Diagnostic Type (Biopsy & Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers), Indication, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

The Global Cancer Diagnostics Market size was estimated at USD 178.19 billion in 2022 and expected to reach USD 193.81 billion in 2023, projecting growth at a CAGR of 8.90% to reach USD 352.59 billion by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Cancer Diagnostics Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Cancer Diagnostics Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Cancer Diagnostics Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Cancer Diagnostics Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the Global Cancer Diagnostics Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Diagnostic Type, the market is studied across Biopsy & Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers.

Based on Indication, the market is studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.

Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Cancer Diagnostics Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Cancer Diagnostics Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Cancer Diagnostics Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Cancer Diagnostics Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Diagnostics Market, including Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson & Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic Inc., Illumina Inc., Koninklijke Philips N.V., Myriad Genetics, Natera, Inc., Personal Genome Diagnostics Inc., Qiagen NV, Quest Diagnostics, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer Diagnostics Market?
6. What is the market share of the leading vendors in the Global Cancer Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Cancer Diagnostics Market?

Table of contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising aging population and increasing prevalence of cancer
5.1.1.2. Increasing government initiatives for funding and awareness about cancer treatment
5.1.1.3. Growing medical tourism in emerging economies
5.1.2. Restraints
5.1.2.1. High cost of diagnostic imaging systems
5.1.3. Opportunities
5.1.3.1. Emerging nanotechnology in cancer diagnosis
5.1.3.2. Rise in the amalgamation strategies by the market players in the cancer diagnostics
5.1.4. Challenges
5.1.4.1. Inadequate access to cancer detection and high treatment costs in lower income countries
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Cancer Diagnostics Market, by Diagnostic Type
6.1. Introduction
6.2. Biopsy & Cytology Test
6.3. Diagnostic Imaging Test
6.4. Tumor Biomarkers

7. Cancer Diagnostics Market, by Indication
7.1. Introduction
7.2. Blood Cancer
7.3. Breast Cancer
7.4. Cervical Cancer
7.5. Colorectal Cancer
7.6. Kidney Cancer
7.7. Liver Cancer
7.8. Lung Cancer
7.9. Ovarian Cancer
7.10. Pancreatic Cancer
7.11. Prostate Cancer
7.12. Skin Cancer

8. Americas Cancer Diagnostics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Cancer Diagnostics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Cancer Diagnostics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Product Portfolio Analysis, By Key Player
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Abbott Laboratories
12.2. Agilent Technologies Inc.
12.3. Becton Dickinson & Company
12.4. F. Hoffmann-La Roche Ltd
12.5. GE Healthcare
12.6. Hologic Inc.
12.7. Illumina Inc.
12.8. Koninklijke Philips N.V.
12.9. Myriad Genetics
12.10. Natera, Inc.
12.11. Personal Genome Diagnostics Inc.
12.12. Qiagen NV
12.13. Quest Diagnostics
12.14. Siemens Healthcare GmbH
12.15. Thermo Fisher Scientific Inc.

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures

FIGURE 1. GLOBAL CANCER DIAGNOSTICS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 6. GLOBAL CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 9. GLOBAL CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL CANCER DIAGNOSTICS MARKET DYNAMICS
FIGURE 11. GLOBAL CANCER DIAGNOSTICS MARKET PORTER'S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2022 VS 2030 (%)
FIGURE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 14. GLOBAL CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY DIAGNOSTIC TYPE, 2030
FIGURE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY & CYTOLOGY TEST, 2018-2030 (USD BILLION)
FIGURE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TEST, 2018-2030 (USD BILLION)
FIGURE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR BIOMARKERS, 2018-2030 (USD BILLION)
FIGURE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 20. GLOBAL CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2030
FIGURE 21. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD BILLION)
FIGURE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD BILLION)
FIGURE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, 2018-2030 (USD BILLION)
FIGURE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD BILLION)
FIGURE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, 2018-2030 (USD BILLION)
FIGURE 26. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD BILLION)
FIGURE 27. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD BILLION)
FIGURE 28. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD BILLION)
FIGURE 29. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD BILLION)
FIGURE 30. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD BILLION)
FIGURE 31. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, 2018-2030 (USD BILLION)
FIGURE 32. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 33. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 34. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 35. AMERICAS CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 36. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 37. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 38. CANADA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 39. MEXICO CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 40. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 41. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 42. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 43. UNITED STATES CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 44. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 45. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 46. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 47. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 48. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 49. CHINA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 50. INDIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 51. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 52. JAPAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 53. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 54. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 55. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 56. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 57. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 58. THAILAND CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 59. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 63. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 64. DENMARK CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 65. EGYPT CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 66. FINLAND CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 67. FRANCE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 68. GERMANY CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 69. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 70. ITALY CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 71. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 72. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 73. NORWAY CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 74. POLAND CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 75. QATAR CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 76. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 77. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 78. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 79. SPAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 80. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 81. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 82. TURKEY CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 83. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 84. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 85. GLOBAL CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 86. GLOBAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 87. GLOBAL CANCER DIAGNOSTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

List of Tables

TABLE 1. GLOBAL CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD BILLION)
TABLE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY & CYTOLOGY TEST, 2018-2030 (USD BILLION)
TABLE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY & CYTOLOGY TEST, BY REGION, 2018-2030 (USD BILLION)
TABLE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY & CYTOLOGY TEST, BY REGION, 2018-2030 (USD BILLION)
TABLE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TEST, 2018-2030 (USD BILLION)
TABLE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TEST, BY REGION, 2018-2030 (USD BILLION)
TABLE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TEST, BY REGION, 2018-2030 (USD BILLION)
TABLE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR BIOMARKERS, 2018-2030 (USD BILLION)
TABLE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR BIOMARKERS, BY REGION, 2018-2030 (USD BILLION)
TABLE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR BIOMARKERS, BY REGION, 2018-2030 (USD BILLION)
TABLE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD BILLION)
TABLE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 20. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD BILLION)
TABLE 21. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, 2018-2030 (USD BILLION)
TABLE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 26. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD BILLION)
TABLE 27. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 28. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 29. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, 2018-2030 (USD BILLION)
TABLE 30. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 31. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 32. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD BILLION)
TABLE 33. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 34. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 35. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD BILLION)
TABLE 36. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 37. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 38. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD BILLION)
TABLE 39. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 40. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 41. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD BILLION)
TABLE 42. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 43. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 44. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD BILLION)
TABLE 45. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 46. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 47. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, 2018-2030 (USD BILLION)
TABLE 48. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 49. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 50. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 51. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 52. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 53. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 54. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 55. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 56. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 57. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 58. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 59. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 60. CANADA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 61. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 62. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 63. MEXICO CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 64. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 65. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 66. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 67. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD BILLION)
TABLE 68. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 69. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 70. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 71. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 72. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 73. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 74. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 75. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 76. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 77. CHINA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 78. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 79. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 80. INDIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 81. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 82. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 83. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 84. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 85. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 86. JAPAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 87. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 88. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 89. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 90. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 91. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 92. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 93. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 94. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 95. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 96. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 97. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 98. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 99. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 100. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 101. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 102. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 103. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 104. THAILAND CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 105. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 106. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 107. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 108. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 109. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 114. DENMARK CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 115. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 116. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 117. EGYPT CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 118. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 119. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 120. FINLAND CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 121. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 122. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 123. FRANCE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 124. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 125. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 126. GERMANY CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 127. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 128. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 129. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 130. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 131. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 132. ITALY CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 133. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 134. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 135. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 136. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 137. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 138. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 139. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 140. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 141. NORWAY CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 142. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 143. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 144. POLAND CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 145. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 146. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 147. QATAR CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 148. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 149. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 150. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 151. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 152. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 153. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 154. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 155. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 156. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 157. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 158. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 159. SPAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 160. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 161. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 162. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 163. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 164. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 165. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 166. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 167. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 168. TURKEY CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 169. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 170. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 171. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 172. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 173. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 174. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 175. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 176. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 177. GLOBAL CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 178. GLOBAL CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 179. GLOBAL CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 180. GLOBAL CANCER DIAGNOSTICS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 181. GLOBAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 182. GLOBAL CANCER DIAGNOSTICS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 183. GLOBAL CANCER DIAGNOSTICS MARKET MERGER & ACQUISITION
TABLE 184. GLOBAL CANCER DIAGNOSTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 185. GLOBAL CANCER DIAGNOSTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 186. GLOBAL CANCER DIAGNOSTICS MARKET INVESTMENT & FUNDING
TABLE 187. GLOBAL CANCER DIAGNOSTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 188. GLOBAL CANCER DIAGNOSTICS MARKET: LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
Agilent Technologies Inc.
Becton Dickinson & Company
F. Hoffmann-La Roche Ltd
GE Healthcare
Hologic Inc.
Illumina Inc.
Koninklijke Philips N.V.
Myriad Genetics
Natera, Inc.
Personal Genome Diagnostics Inc.
Qiagen NV
Quest Diagnostics
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc.

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.